X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (93) 93
female (81) 81
male (80) 80
aged (75) 75
middle aged (72) 72
oncology (59) 59
adult (55) 55
lung neoplasms - drug therapy (49) 49
lung neoplasms - pathology (46) 46
lung cancer (40) 40
aged, 80 and over (38) 38
carcinoma, non-small-cell lung - drug therapy (35) 35
antineoplastic combined chemotherapy protocols - therapeutic use (34) 34
index medicus (30) 30
cancer (27) 27
camptothecin - analogs & derivatives (25) 25
prognosis (25) 25
chemotherapy (24) 24
lung neoplasms - mortality (24) 24
survival rate (22) 22
carcinoma, non-small-cell lung - pathology (21) 21
irinotecan (21) 21
adenocarcinoma (20) 20
camptothecin - administration & dosage (20) 20
treatment outcome (20) 20
adenocarcinoma - pathology (19) 19
cisplatin (19) 19
antineoplastic combined chemotherapy protocols - adverse effects (18) 18
neoplasm staging (18) 18
lung neoplasms - genetics (17) 17
survival analysis (14) 14
lung neoplasms - surgery (13) 13
carcinoma, non-small-cell lung - mortality (12) 12
cisplatin - administration & dosage (12) 12
lung neoplasms - metabolism (12) 12
retrospective studies (12) 12
thin-section ct (12) 12
carcinoma, small cell - drug therapy (10) 10
disease-free survival (10) 10
organoplatinum compounds - administration & dosage (10) 10
pharmacology & pharmacy (10) 10
adenocarcinoma - mortality (9) 9
carcinoma (9) 9
carcinoma, non-small-cell lung - genetics (9) 9
lung adenocarcinoma (9) 9
nedaplatin (9) 9
respiratory system (9) 9
survival (9) 9
adenocarcinoma - diagnostic imaging (8) 8
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
camptothecin (8) 8
cpt-11 (8) 8
lung (8) 8
lung neoplasms - diagnosis (8) 8
lung neoplasms - diagnostic imaging (8) 8
mutations (8) 8
polymerase chain reaction (8) 8
tomography, x-ray computed - methods (8) 8
trial (8) 8
adenocarcinoma - drug therapy (7) 7
adenocarcinoma - metabolism (7) 7
antineoplastic agents - therapeutic use (7) 7
camptothecin - adverse effects (7) 7
cell lung-cancer (7) 7
combination (7) 7
dose-response relationship, drug (7) 7
gefitinib (7) 7
lung cancer, non-small cell (7) 7
mutation (7) 7
paclitaxel (7) 7
prospective studies (7) 7
research (7) 7
tumors (7) 7
adenocarcinoma - genetics (6) 6
adenocarcinoma - surgery (6) 6
adenocarcinoma of lung (6) 6
antineoplastic agents, phytogenic - administration & dosage (6) 6
cancer research (6) 6
carcinoma, non-small-cell lung - surgery (6) 6
dna damage (6) 6
etoposide (6) 6
etoposide - administration & dosage (6) 6
expression (6) 6
granulocyte colony-stimulating factor - therapeutic use (6) 6
ground-glass opacity (6) 6
japan (6) 6
neutropenia - chemically induced (6) 6
oncology, experimental (6) 6
organoplatinum compounds - adverse effects (6) 6
organoplatinum compounds - therapeutic use (6) 6
radiology, nuclear medicine & medical imaging (6) 6
time factors (6) 6
tumor cells, cultured (6) 6
vindesine - administration & dosage (6) 6
adjuvant chemotherapy (5) 5
analysis of variance (5) 5
base sequence (5) 5
camptothecin - therapeutic use (5) 5
carcinoma, small cell - pathology (5) 5
carcinoma, squamous cell - drug therapy (5) 5
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 2011, Volume 6, Issue 9, p. e24143
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 1/2018, Volume 81, Issue 1, pp. 81 - 87
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2016, Volume 34, Issue 15_suppl, pp. e20581 - e20581
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 3/2013, Volume 71, Issue 3, pp. 705 - 711
Both amrubicin (Am) and S-1 are effective against non-small-cell lung cancer (NSCLC), and preclinical studies have demonstrated that the effect of... 
Amrubicin | Medicine & Public Health | NSCLC | S-1 | Oncology | Cancer Research | Second-line | Pharmacology/Toxicology | 9-AMINOANTHRACYCLINE | CARBOPLATIN | BEVACIZUMAB | ANTITUMOR-ACTIVITY | DOCETAXEL | CISPLATIN PLUS GEMCITABINE | 9-AMINO-ANTHRACYCLINE | INHIBITION | ONCOLOGY | ONCOLOGY GROUP WJTOG | PHARMACOLOGY & PHARMACY | III TRIAL | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Antimetabolites, Antineoplastic - administration & dosage | Dose-Response Relationship, Drug | Mutation - physiology | Anthracyclines - administration & dosage | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Oxonic Acid - administration & dosage | Mutation - genetics | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Tegafur - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Drug Combinations | Chemotherapy | Genetic aspects | Bilirubin | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
BMC Cancer, ISSN 1471-2407, 10/2015, Volume 15, Issue 1, p. 740
Journal Article
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 07/2013, Volume 8, Issue 7, pp. 980 - 984
Journal Article
Annals of Oncology, ISSN 0923-7534, 10/2014, Volume 25, Issue suppl_5, pp. v81 - v81
Journal Article
Journal Article
Journal of Proteomics, ISSN 1874-3919, 04/2016, Volume 139, pp. 60 - 66
Lung cancer is generally considered as a highly malignant cancer. A major challenge for the management of lung adenocarcinoma patients is to predict the... 
MRM analysis | Phosphorylation | Biomarker | Lung adenocarcinoma | Shotgun LC–MS/MS analysis | Therapeutic target | Shotgun LC-MS/MS analysis | Adenocarcinoma | Proteins | Antigens | Spermatozoa | Lung cancer | Health aspects | Mass spectrometry
Journal Article
International Journal of Molecular Medicine, ISSN 1107-3756, 08/2011, Volume 28, Issue 2, pp. 181 - 186
Periostin (PN), a secreted adhesion-related protein expressed in the periosteum and periodontal ligaments, acts as a critical regulator of the formation and... 
Anti-periostin antibody | Breast cancer | Periostin | anti-periostin antibody | MEDICINE, RESEARCH & EXPERIMENTAL | INVASION | PROTEIN | ANGIOGENESIS | periostin | GROWTH | ACUTE MYOCARDIAL-INFARCTION | breast cancer | BONE | EXPRESSION
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2017, Volume 35, Issue 32, pp. 3662 - 3670
Journal Article